ranQ
ranQ
ranQ
DirectoryIndustriesPlacesKnowledgeComparisonsSoon
Sign inCheck visibility
ranQHSG Startup LabelRecognised by the
HSG Startup Label

The leading AI company directory, built to boost AI visibility.

DEENFRIT
Product
  • Pricing
  • Directory
  • Industries
  • Trust Score
Company
  • About
  • Partner program
  • Contact
  • Legal
© 2026 cohaga AG · All Rights Reserved · St. Gallen, Switzerland · Imprint747,212 companies indexed · Last updated: today
DirectoryIndustryPharmaceutical companyLausanneBiodelphis Therapeutics SA
Biodelphis Therapeutics SA Logo
Verified· 3 sourcesTrust Score
Summary

About the company

Biodelphis Therapeutics SA develops antibody-peptide conjugates as targeted protease inhibitors for drug therapies. Its preclinical pipeline includes drug candidates targeting cathepsins, with potential applications in oncology and osteoporosis.

AI-generated
Presence

Service area

Offering

Products & services

Industry:Pharmaceutical company
LeadhubOutbound Leads by COHAGA

Looking for direct email addresses and phone numbers?

Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.

Discover Leadhub
3.4/5

Biodelphis Therapeutics SA

✓ Offered3
Protease Inhibitor Platform (APICore)
APICore drug discovery platform for targeted protease inhibitors and antibody-peptide inhibitor conjugates; supports selective candidates with targeted delivery and reduced off-tissue toxicity.
Preclinical Drug Pipeline
Preclinical pipeline with four first-in-class drug candidates against cathepsin proteases B, S, K and L, with in vivo proof-of-concept data for oncology, osteoporosis and autoimmune indications.
Drug Development for Oncology and Other Indications
Drug development for cancer and other diseases; focus on lung adenocarcinoma, osteoporosis and autoimmune disorders using preclinical candidates based on the APIC platform.
Trust & reputation

ranQ Trust Score of Biodelphis Therapeutics SA: 3.4 out of 5.0

Trust Score3.4/ 5.0

Solid

x

Data basis 58% · As of November 2026

Biodelphis Therapeutics SA has no value in the Reputation area of the ranQ Trust Score because no data is available. The area carries 42% of the weighting and drops out of the calculation for this profile; it does not lower the score, only the reported data basis.
x
CriterionValueWeight
  • Review quality: No data point — the criterion is taken out of the weighting and does not lower the score.—24%
  • Review volume: No data point — the criterion is taken out of the weighting and does not lower the score.—10%
  • Review recency: No data point — the criterion is taken out of the weighting and does not lower the score.—8%
Biodelphis Therapeutics SA scores 42.7 out of 100 points in the Substance area of the ranQ Trust Score. This area carries 28% of the weighting.
x
CriterionValueWeight
  • Establishment: Years since founding or brand launch, logarithmic. The maximum is reached at 15 years.0.012%
  • Company size: The headcount band, researched by ranQ or stated by the company. It is scored in steps rather than by head count, because the data only provides bands.55.07%
Biodelphis Therapeutics SA scores 86.7 out of 100 points in the Identity area of the ranQ Trust Score. This area carries 22% of the weighting.
x
CriterionValueWeight
  • Verification: Official register entry (commercial register with UID or professional-body record, 55 points), confirmed domain (20 points) and confirmed ranQ profile (up to 25 points, depending on completeness).86.722%
Biodelphis Therapeutics SA scores 14.2 out of 100 points in the Visibility area of the ranQ Trust Score. This area carries 8% of the weighting.
x
CriterionValueWeight
  • Website authority: Ahrefs' Domain Rating measures, on a scale of 0 to 100, how strongly a website is linked from other websites. For Swiss SMEs the range up to 40 is typical; the maximum is reached at 35.8.34%
  • Media authority: Quality and number of editorial mentions, weighted by the importance of the source, plus the recency of the latest high-quality mention.20.04%
Qualifications+0.00

Biodelphis Therapeutics SA reaches a ranQ Trust Score of 3.4 out of 5.0 — rated «Solid». No public customer reviews are available for this provider; the rating is based on the remaining criteria. The data basis is 58%, so the score is backed by part of the criteria. As of November 2026.

The Trust Score cannot be bought and is calculated from publicly verifiable data.

Press

Media

May 4, 2026Media
Strategic Investments to advance Biodelphis Therapeutics Development
startupticker.ch

Knowledge

No knowledge articles yet

Once Biodelphis Therapeutics SA has claimed this profile, we'll publish editorial articles and case studies here together.

Get started
Comparisons

Biodelphis Therapeutics SA in comparison

Soon

Industry comparisons are coming soon

We're preparing industry comparisons that rank Biodelphis Therapeutics SA by reviews, experience and specialisations.

Is this your company?

Claim the company profile of Biodelphis Therapeutics SA to make its contact details visible. With a plan we additionally create and publish industry comparisons, articles and much more.

Secure profile

Location

Avenue Frédéric-Recordon 32
1004 Lausanne

At a glance

Legal form
Corporation
UID
CHE-444.253.910
Founded
2026 · 0 years
Last commercial register change
April 17, 2026
Employees
1 to 10

Active in 1 of 26 cantons

  • VDVaud
Legal form: Graded by liability and disclosure. The weight is kept small: a sole proprietorship is not a dubious company, it is just liable differently.
100.0
6%
  • Branch offices: Branch offices linked in the commercial register. Having none is normal and costs no points.70.03%
  • Full methodology

    Similar companies

    OB
    Opna Bio Switzerland Sàrl
    Epalinges
    OT
    Onward Therapeutics SA
    Epalinges
    LH
    Legacy Healthcare (Switzerland) SA
    Epalinges
    DI
    Debiopharm International SA
    Lausanne
    HS
    HemostOD SA
    St-Sulpice Vd
    GM
    Grand Medical Group AG
    Lausanne
    OO
    Oculis Operations Sàrl
    Lausanne
    ST
    Synameta Therapeutics SARL
    Epalinges